Vineet R. Jindal net worth and biography

Vineet Jindal Biography and Net Worth

Vineet R. Jindal founded Stockr, Inc. and Bay Street Advisors, Inc. Presently, he holds the position of Chief Financial Officer for Reneo Pharmaceuticals, Inc.

Mr. Jindal previously held the position of Chief Executive Officer & Director at Stockr, Inc., Vice President-Corporate Communications & Strategy at Reata Pharmaceuticals, Inc., Chief Business Officer at Caliber Corporate Advisers LLC, President, Chief Executive Officer & Director at Viper Gold Ltd., President, Chief Executive Officer & Director at QuikFlo Health, Inc., Principal at Boston Millennia Partners, Analyst at Wedbush Securities, Inc. and Principal at ThinkEquity Partners.

Vineet R. Jindal received a graduate degree from Cornell University and an undergraduate degree and a graduate degree from the University of California, Berkeley.

What is Vineet R. Jindal's net worth?: The estimated net worth of Vineet R. Jindal is at least $9,100.00 as of August 25th, 2021. Mr. Jindal owns 5,000 shares of Reneo Pharmaceuticals stock worth more than $9,100 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Jindal may own. Learn More about Vineet R. Jindal's net worth.
How do I contact Vineet R. Jindal?: The corporate mailing address for Mr. Jindal and other Reneo Pharmaceuticals executives is , , . Reneo Pharmaceuticals can also be reached via phone at 858-283-0280 and via email at [email protected]. Learn More on Vineet R. Jindal's contact information.
Has Vineet R. Jindal been buying or selling shares of Reneo Pharmaceuticals?: Vineet R. Jindal has not been actively trading shares of Reneo Pharmaceuticals during the past quarter. Most recently, on Wednesday, August 25th, Vineet R. Jindal bought 5,000 shares of Reneo Pharmaceuticals stock. The stock was acquired at an average cost of $7.44 per share, with a total value of $37,200.00. Following the completion of the transaction, the chief financial officer now directly owns 5,000 shares of the company's stock, valued at $37,200. Learn More on Vineet R. Jindal's trading history.
Who are Reneo Pharmaceuticals' active insiders?: Reneo Pharmaceuticals' insider roster includes Michael Cruse (VP), Gregory Flesher (CEO), Vineet Jindal (CFO), and Bali Muralidhar (Director). Learn More on Reneo Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reneo Pharmaceuticals?: In the last twelve months, Reneo Pharmaceuticals insiders bought shares 4 times. They purchased a total of 670,520 shares worth more than $993,097.95. The most recent insider tranaction occured on September, 24th when Major Shareholder Braden Michael Leonard bought 29,600 shares worth more than $41,736.00. Insiders at Reneo Pharmaceuticals own 17.9% of the company. Learn More about insider trades at Reneo Pharmaceuticals.
Information on this page was last updated on 9/24/2024.

Vineet R. Jindal Insider Trading History at Reneo Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/25/2021	Buy	5,000	$7.44	$37,200.00	5,000

Vineet R. Jindal Buying and Selling Activity at Reneo Pharmaceuticals

Reneo Pharmaceuticals Company Overview

Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.

Today's Range

Now: $1.82

$1.68

$1.90

50 Day Range

MA: $1.64

$1.31

$1.82

2 Week Range

Now: $1.82

$0.98

$9.21

Volume

437,500 shs

Average Volume

250,384 shs

Market Capitalization

$60.84 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.